Cargando…
HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study
BACKGROUND: Determining treatment response for patients with hidradenitis suppurativa (HS) can be challenging due to limitations of current disease activity evaluations. OBJECTIVE: Evaluate the novel, validated endpoint, Hidradenitis Suppurativa Clinical Response (HiSCR) and its utility as an outcom...
Autores principales: | Kimball, A.B., Sobell, J.M., Zouboulis, C.C., Gu, Y., Williams, D.A., Sundaram, M., Teixeira, H.D., Jemec, G.B.E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034809/ https://www.ncbi.nlm.nih.gov/pubmed/26201313 http://dx.doi.org/10.1111/jdv.13216 |
Ejemplares similares
-
Hidradenitis suppurativa and intimacy
por: Jemec, G.
Publicado: (2018) -
Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa
por: Gulliver, Wayne, et al.
Publicado: (2016) -
Multimodal management of hidradenitis suppurativa
por: Jemec, Gregor B.E.
Publicado: (2020) -
Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities
por: Crowley, JJ, et al.
Publicado: (2014) -
Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab
por: Gorovoy, Ian, et al.
Publicado: (2009)